RenovoRx Inc RNXT
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-08-17 |
| Shares Out. | 45,050,000 |
| Website | renovorx.com/ ↗ |
| Phone | 14088002649 |
| Employees | 17 |
| Revenue | $909,000 |
| Gross Profit | $766,000 |
| Net Income | -$2.9M |
| Free Cash Flow | -$11.9M |
| Total Assets | $11.5M |
| Total Liabilities | $2.5M |
| Equity | $9.0M |
About RenovoRx Inc
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
RenovoRx Inc is a publicly traded company under the ticker symbol RNXT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-09-01)